Multimodal therapy and targeted inhibitors show modest activity for pediatric malignant rhabdoid tumor of the kidney
New Targeted Therapies Show Potential for Rare Kidney Tumors
This mini review examines multimodal therapies, EZH2 inhibition, and CDK4/6 blockade for pediatric patients with malignant rhabdoid tumor of…
Targeted treatments like EZH2 and CDK4/6 inhibitors may offer new options for children with a rare type of kidney cancer.
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer
Switching drugs offers hope for advanced breast cancer patients facing treatment failure
This meta-analysis synthesizes data from phase II and III clinical trials involving 1396 patients with hormone receptor-positive, HER2-negat…
A large review found that restarting a specific cancer drug after stopping it can delay disease growth by nearly two months compared to stan…
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.